MA26876A1 - Mesylate et formes polymorphes de 4-amino-6, 7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydro-isoquinol-2-yl)-5-(2-pyridyl)quinazoline - Google Patents

Mesylate et formes polymorphes de 4-amino-6, 7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydro-isoquinol-2-yl)-5-(2-pyridyl)quinazoline

Info

Publication number
MA26876A1
MA26876A1 MA26776A MA26776A MA26876A1 MA 26876 A1 MA26876 A1 MA 26876A1 MA 26776 A MA26776 A MA 26776A MA 26776 A MA26776 A MA 26776A MA 26876 A1 MA26876 A1 MA 26876A1
Authority
MA
Morocco
Prior art keywords
isoquinol
quinazoline
mesylate
dimethoxy
tetrahydro
Prior art date
Application number
MA26776A
Other languages
English (en)
Inventor
Ann Basford Patricia
Blaise Hodgson Paul
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0005200A external-priority patent/GB0005200D0/en
Priority claimed from GB0015900A external-priority patent/GB0015900D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of MA26876A1 publication Critical patent/MA26876A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

DEPOSANT Société dite : PFIZER INC. REVENDICATION DE PRIORITES GB 3 Mars 2000 0005200.1 GB 28 Juin 2000 0015900.4 Voir en annexe le titre de l'invention et le texte de l'abrégé Mésylate et formes polymorphes de 4-amino-6,7-diméthoxy-2-(5-méthanesulfonamido-1,2,3,4-tétrahydro-isoquinol-2-yl)-5-(2-pyridyl)quinazoline La présente invention propose le mésylate de 4-amino-6,7-diméthoxy-2-(5-méthanesuifonamido-1,2,3,4-tétrahydro-isoquinol-2-yl)-5-(2-pyridyl)quinazoline de formule (1), conjointement avec des procédés de préparation, et des compositions le contenant. L'invention concerne également des formes polymorphes cristallines anhydres substantiellement pures de la base libre. Les composés sont particulièrement utiles dans le traitement de l'hyperplasie prostatique bénigne.
MA26776A 2000-03-03 2002-08-15 Mesylate et formes polymorphes de 4-amino-6, 7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydro-isoquinol-2-yl)-5-(2-pyridyl)quinazoline MA26876A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0005200A GB0005200D0 (en) 2000-03-03 2000-03-03 New salt form
GB0015900A GB0015900D0 (en) 2000-06-28 2000-06-28 New salt form

Publications (1)

Publication Number Publication Date
MA26876A1 true MA26876A1 (fr) 2004-12-20

Family

ID=26243792

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26776A MA26876A1 (fr) 2000-03-03 2002-08-15 Mesylate et formes polymorphes de 4-amino-6, 7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydro-isoquinol-2-yl)-5-(2-pyridyl)quinazoline

Country Status (39)

Country Link
US (1) US6683085B2 (fr)
EP (1) EP1268468B1 (fr)
JP (1) JP3857919B2 (fr)
KR (1) KR100496089B1 (fr)
CN (1) CN1214029C (fr)
AP (1) AP2002002611A0 (fr)
AR (1) AR029482A1 (fr)
AT (1) ATE253570T1 (fr)
AU (1) AU779118B2 (fr)
BG (1) BG106869A (fr)
BR (1) BR0108910A (fr)
CA (1) CA2398963C (fr)
CR (1) CR6731A (fr)
CZ (1) CZ20022858A3 (fr)
DE (1) DE60101157T2 (fr)
DK (1) DK1268468T3 (fr)
EA (1) EA004748B1 (fr)
EE (1) EE200200496A (fr)
ES (1) ES2208565T3 (fr)
GE (1) GEP20043364B (fr)
HN (1) HN2001000036A (fr)
HR (1) HRP20020718A2 (fr)
HU (1) HUP0300006A3 (fr)
IL (1) IL150634A0 (fr)
IS (1) IS6441A (fr)
MA (1) MA26876A1 (fr)
MX (1) MXPA02008665A (fr)
NO (1) NO20024195L (fr)
NZ (1) NZ519672A (fr)
OA (1) OA12186A (fr)
PE (1) PE20011225A1 (fr)
PL (1) PL365070A1 (fr)
PT (1) PT1268468E (fr)
SI (1) SI1268468T1 (fr)
SK (1) SK12282002A3 (fr)
TN (1) TNSN01034A1 (fr)
TR (1) TR200302130T4 (fr)
UA (1) UA72311C2 (fr)
WO (1) WO2001064672A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124455D0 (en) * 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
US7163696B2 (en) 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
DE10223913A1 (de) 2002-05-29 2003-12-11 Bayer Cropscience Ag Verfahren zur Herstellung spezifischer Kristallmodifikationen polymorpher Substanzen
GB0221582D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Method of treatment
AR043880A1 (es) * 2003-04-22 2005-08-17 Solvay Pharm Gmbh Mesilato acido de 4-(4.trans-hidroxiciclohexil) amino-2-fenil-7h-pirrolo (2,3-d) pirimidina y sus formas polimorfas
WO2005089804A2 (fr) * 2004-03-16 2005-09-29 Pfizer Limited Combinaisons d'inhibiteurs de la reductase hmg-coa et d'antagonistes du recepteur adrenergique $g(a)1
CN101584696A (zh) * 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
CN105596301A (zh) * 2016-01-29 2016-05-25 中国药科大学 一种以异喹啉为基本骨架的p2x7受体拮抗剂的纳米混悬剂及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914114A (en) 1984-05-28 1990-04-03 Merck Patent Gesellschaft Mit Breschrankter Haftung 3-[4-(4-phenyl-1,2,3,6-tetrahydro-1-pyridyl)butyl]-5-hydroxy-indole methanesulfonate having sedating and anti-parkinsonism properties
KR950011409B1 (ko) * 1986-09-16 1995-10-04 메르크 파텐트 게젤샤프트 미트 베슈랭크터 하프퉁 히드록시인돌 유도체
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
EP1268468A1 (fr) 2003-01-02
JP3857919B2 (ja) 2006-12-13
CA2398963A1 (fr) 2001-09-07
BG106869A (bg) 2002-12-29
NO20024195D0 (no) 2002-09-03
AU779118B2 (en) 2005-01-06
ES2208565T3 (es) 2004-06-16
PL365070A1 (en) 2004-12-27
HRP20020718A2 (en) 2004-02-29
IS6441A (is) 2002-06-25
EA200200826A1 (ru) 2003-02-27
UA72311C2 (uk) 2005-02-15
WO2001064672A1 (fr) 2001-09-07
HUP0300006A2 (en) 2003-05-28
IL150634A0 (en) 2003-02-12
AU3588801A (en) 2001-09-12
CR6731A (es) 2004-03-11
DE60101157D1 (de) 2003-12-11
EE200200496A (et) 2004-02-16
US20020010188A1 (en) 2002-01-24
KR20020080463A (ko) 2002-10-23
NZ519672A (en) 2004-06-25
PE20011225A1 (es) 2001-12-08
GEP20043364B (en) 2004-03-10
ATE253570T1 (de) 2003-11-15
AR029482A1 (es) 2003-07-02
PT1268468E (pt) 2004-01-30
HUP0300006A3 (en) 2006-01-30
BR0108910A (pt) 2002-12-24
HN2001000036A (es) 2001-07-09
DK1268468T3 (da) 2004-02-09
NO20024195L (no) 2002-09-03
JP2003525289A (ja) 2003-08-26
HK1053655A1 (en) 2003-10-31
SI1268468T1 (en) 2004-04-30
DE60101157T2 (de) 2004-09-02
CN1214029C (zh) 2005-08-10
TR200302130T4 (tr) 2004-01-21
EP1268468B1 (fr) 2003-11-05
AP2002002611A0 (en) 2002-09-30
TNSN01034A1 (fr) 2005-11-10
MXPA02008665A (es) 2003-02-24
SK12282002A3 (sk) 2003-10-07
US6683085B2 (en) 2004-01-27
OA12186A (en) 2006-05-09
CA2398963C (fr) 2006-10-24
KR100496089B1 (ko) 2005-06-17
EA004748B1 (ru) 2004-08-26
CN1432010A (zh) 2003-07-23
CZ20022858A3 (cs) 2003-09-17

Similar Documents

Publication Publication Date Title
MA26873A1 (fr) Derives de purine
MA27174A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4.
MA27452A1 (fr) Derives d'indole servant d'agonistes beta-2
MA27190A1 (fr) Derives de tropane servant de modulateurs de ccr5
MA27009A1 (fr) Derives de pyrazole pour le traitement d'une infection par le vih
MA27439A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
ATE228507T1 (de) Substituierte 6-phenylphenanthridine
MA27883A1 (fr) Derives de pyrido [2,1-a] isoquinoline utilises comme inhibiteurs de dpp-iv
DE60137966D1 (de) Anilinopyrimidin derivate als "jnk pathway inhibitoren", zusammensetzungen und damit verbundene behandlungsmethoden
TNSN07021A1 (fr) Derives de quinazoline -4-yl-piperidine et cinnoline -4-yl-piperidine servant d'inhibiteurs de pde10 pour le traitement de troubles du snc
DE60108236D1 (de) 1,2,3,4-tetrahydroisochinolin-derivate
TNSN07235A1 (en) Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
MA27138A1 (fr) Composes heteroaryliques condenses a substituant azabicyclique pour le traitement d'une maladie
MA27135A1 (fr) Agents antidiabetiques oraux
MA26701A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.
MA27840A1 (fr) Derives de (2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propylphenyle servant d'agonistes beta2
MA27141A1 (fr) DERIVES DE 3-AZABICYCLO[3.1.0]HEXANE SERVANT D'ANTAGONISTES DES RECEPTEURS D'OPIOiDES
MA26876A1 (fr) Mesylate et formes polymorphes de 4-amino-6, 7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydro-isoquinol-2-yl)-5-(2-pyridyl)quinazoline
DE69919349D1 (de) Piperidinyl- und n-amidinopiperidinyl-derivate
TW200612904A (en) Hair growth promoting agents
MA27435A1 (fr) DERIVES DE 4-(3,5-DICYANOPHENOXY) PYRAZOLE DESTINES A eTRE UTILISES COMME MODULATEURS DE TRANSCRIPTASE DANS LE TRAITEMENT D'AFFECTIONS PROVOQUEES PAR LE VIH
MA27074A1 (fr) 2-amino-6(phenyl-2,4,5-substitue)-pyridines destinées a etre utilisees comme inhibiteurs de l'oxyde nitrique-synthase
PY0104579A (es) Nueva forma de sal y polimorfos
CO5221124A1 (es) Nueva forma de sal y polimorfos
UY26604A1 (es) Nueva forma de sal y polimorfos